Checkpoint Blockade Cancer Immunotherapy Targets Tumor-Specific Mutant Antigens
RNA-seq (gene expression) · mouse · 22 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 22 samples: 8 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE62771_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA265091 and SRA study SRP049335. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 22 samples.
How we read this: 8 replicated groups read from 22 sample titles; they account for 22 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM1533190 aCTLA4_mLama4_neg_rep1 aCTLA4_mLama4_neg
- GSM1533191 aCTLA4_mLama4_neg_rep2 aCTLA4_mLama4_neg
- GSM1533192 aCTLA4_mLama4_neg_rep3 aCTLA4_mLama4_neg
- GSM1533193 aCTLA4_mLama4_pos_rep1 aCTLA4_mLama4_pos
- GSM1533194 aCTLA4_mLama4_pos_rep2 aCTLA4_mLama4_pos
- GSM1533195 aCTLA4_mLama4_pos_rep3 aCTLA4_mLama4_pos
- GSM1533196 aPD1_mLama4_neg_rep1 aPD1_mLama4_neg
- GSM1533197 aPD1_mLama4_neg_rep2 aPD1_mLama4_neg
- GSM1533198 aPD1_mLama4_neg_rep3 aPD1_mLama4_neg
- GSM1533199 aPD1_mLama4_pos_rep1 aPD1_mLama4_pos
- GSM1533200 aPD1_mLama4_pos_rep2 aPD1_mLama4_pos
- GSM1533201 aPD1_plus_aCTLA4_mLama4_neg_rep1 aPD1_plus_aCTLA4_mLama4…
- GSM1533202 aPD1_plus_aCTLA4_mLama4_neg_rep2 aPD1_plus_aCTLA4_mLama4…
- GSM1533203 aPD1_plus_aCTLA4_mLama4_pos_rep1 aPD1_plus_aCTLA4_mLama4…
- GSM1533204 aPD1_plus_aCTLA4_mLama4_pos_rep2 aPD1_plus_aCTLA4_mLama4…
- GSM1533205 aPD1_plus_aCTLA4_mLama4_pos_rep3 aPD1_plus_aCTLA4_mLama4…
- GSM1533206 Control_Ab_mLama4_neg_rep1 Control_Ab_mLama4_neg
- GSM1533207 Control_Ab_mLama4_neg_rep2 Control_Ab_mLama4_neg
- GSM1533208 Control_Ab_mLama4_neg_rep3 Control_Ab_mLama4_neg
- GSM1533209 Control_Ab_mLama4_pos_rep1 Control_Ab_mLama4_pos
- GSM1533210 Control_Ab_mLama4_pos_rep2 Control_Ab_mLama4_pos
- GSM1533211 Control_Ab_mLama4_pos_rep3 Control_Ab_mLama4_pos
- GSE300288 Single-cell and spatial transcriptomics analysis of tobacco-associated lung adenocarcinoma development, and in response to targeting inflammation alone or in combination with immune checkpoint blockade in precancerous phase [scRNA-seq] 31 samples shares checkpoint, blockade
- GSE290464 Noncanonical role of NCOR1 as a facilitator of DNA mismatch repair and its deficiency sensitizes cancers to immune checkpoint blockade therapy 18 samples shares checkpoint, blockade
- GSE301138 Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy 11 samples shares checkpoint, blockade
- GSE334497 TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer 10 samples shares checkpoint, blockade
- GSE319397 Particle Reprogramming of the TLR–Ferroptosis Axis and Immunometabolic Pathways Inhibits Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer 9 samples shares checkpoint, blockade
- GSE299686 Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma [bulk RNA-seq] 178 samples shares checkpoint, blockade
- GSE299683 Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma [scRNA-seq] 125 samples shares checkpoint, blockade
- GSE235113 Tumor cell intrinsic type I interferon signaling dictates CD47-SIRPα blockade immunotherapy via metabolic reprograming. 22 samples shares immunotherapy, blockade
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.